# Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

> **NCT03813979** · PHASE4 · WITHDRAWN · sponsor: **Radboud University Medical Center**

## Conditions studied

- HIV-1-infection
- Hepatic Impairment

## Interventions

- **DRUG:** Dolutegravir

## Key facts

- **NCT ID:** NCT03813979
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11-15
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** difficult recruitment and delay due to COVID19
- **Last updated:** 2021-06-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03813979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03813979, "Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03813979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*